glp-1 drugs for sleep apnea Episode 75- GLP 1 and GLP-1 drugs and sleep apnea

At MPR 0.5, the adjusted HR was quite similar to that in the main analysis (HR 0.87 [0.71-1.06]), but this became lower at MPR 0.75 (HR 0.75 [0.60 0.95]) and lower yet at MPR 0.95 (HR 0.62 [0.46 0.84]) When excluding subjects with follow-up times shorter than 6 months, 25,390 individuals remained, and the unadjusted HR for MOF was found to be 0.86 [0.731.02] for GLP-1 RAs compared to DPP-4is

Commun., vol

Based on these criteria, Novo Nordisk estimates that approximately 10% of people with obesity would meet the indication

Between 2022 and 2023, prescriptions for phentermine rose 34 percent, according to data shared with CNN from Epic Research

How These Results Compare to Other Weight Loss Medicines Retatrutide's 24.2% mean weight loss at 48 weeks exceeds phase 3 data for semaglutide 2.4 mg (~14.9% at 68 weeks) and is comparable to tirzepatide 15 mg (~22.5% at 72 weeks), though no direct head-to-head trials have been conducted

metformin was generally the background therapy for the majority of subjects